Asymptomatic profound sinus bradycardia (heart rate ≤45) in non-small cell lung cancer patients treated with crizotinib.
Publication
, Journal Article
Ou, S-HI; Azada, M; Dy, J; Stiber, JA
Published in: J Thorac Oncol
December 2011
Crizotinib, a dual MET/ALK inhibitor, is now in advanced clinical development for the treatment of anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer (NSCLC). We have observed several patients who developed profound but asymptomatic sinus bradycardia (HR ≤45) during the course of crizotinib treatment. Herein, we describe the clinical characteristics of three separate patients enrolled in the A8081001 trial (NCT00585195) who developed asymptomatic profound sinus bradycardia with their accompanying electrocardiogram tracings.
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
J Thorac Oncol
DOI
EISSN
1556-1380
Publication Date
December 2011
Volume
6
Issue
12
Start / End Page
2135 / 2137
Location
United States
Related Subject Headings
- Pyridines
- Pyrazoles
- Protein Kinase Inhibitors
- Oncology & Carcinogenesis
- Middle Aged
- Male
- Lung Neoplasms
- Humans
- Female
- Crizotinib
Citation
APA
Chicago
ICMJE
MLA
NLM
Ou, S.-H., Azada, M., Dy, J., & Stiber, J. A. (2011). Asymptomatic profound sinus bradycardia (heart rate ≤45) in non-small cell lung cancer patients treated with crizotinib. J Thorac Oncol, 6(12), 2135–2137. https://doi.org/10.1097/JTO.0b013e3182307e06
Ou, Sai-Hong Ignatius, Michele Azada, Joni Dy, and Jonathan A. Stiber. “Asymptomatic profound sinus bradycardia (heart rate ≤45) in non-small cell lung cancer patients treated with crizotinib.” J Thorac Oncol 6, no. 12 (December 2011): 2135–37. https://doi.org/10.1097/JTO.0b013e3182307e06.
Ou S-HI, Azada M, Dy J, Stiber JA. Asymptomatic profound sinus bradycardia (heart rate ≤45) in non-small cell lung cancer patients treated with crizotinib. J Thorac Oncol. 2011 Dec;6(12):2135–7.
Ou, Sai-Hong Ignatius, et al. “Asymptomatic profound sinus bradycardia (heart rate ≤45) in non-small cell lung cancer patients treated with crizotinib.” J Thorac Oncol, vol. 6, no. 12, Dec. 2011, pp. 2135–37. Pubmed, doi:10.1097/JTO.0b013e3182307e06.
Ou S-HI, Azada M, Dy J, Stiber JA. Asymptomatic profound sinus bradycardia (heart rate ≤45) in non-small cell lung cancer patients treated with crizotinib. J Thorac Oncol. 2011 Dec;6(12):2135–2137.
Published In
J Thorac Oncol
DOI
EISSN
1556-1380
Publication Date
December 2011
Volume
6
Issue
12
Start / End Page
2135 / 2137
Location
United States
Related Subject Headings
- Pyridines
- Pyrazoles
- Protein Kinase Inhibitors
- Oncology & Carcinogenesis
- Middle Aged
- Male
- Lung Neoplasms
- Humans
- Female
- Crizotinib